News stories about Selecta Biosciences (NASDAQ:SELB) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Selecta Biosciences earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.3310049621836 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity raised their price objective on shares of Selecta Biosciences from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, October 12th. Zacks Investment Research upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th. ValuEngine downgraded shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Finally, UBS downgraded shares of Selecta Biosciences from a “buy” rating to a “neutral” rating in a research note on Thursday, November 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Selecta Biosciences currently has an average rating of “Hold” and an average price target of $23.50.

Shares of Selecta Biosciences (NASDAQ SELB) traded down $0.01 during trading on Tuesday, hitting $10.00. 142,000 shares of the stock traded hands, compared to its average volume of 119,154. The company has a debt-to-equity ratio of 0.32, a quick ratio of 9.48 and a current ratio of 9.48. Selecta Biosciences has a twelve month low of $8.70 and a twelve month high of $24.02.

In other Selecta Biosciences news, insider Earl Sands purchased 7,500 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were purchased at an average price of $10.26 per share, for a total transaction of $76,950.00. Following the completion of the purchase, the insider now directly owns 7,500 shares of the company’s stock, valued at $76,950. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Werner Cautreels purchased 20,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were acquired at an average price of $9.31 per share, for a total transaction of $186,200.00. Following the purchase, the insider now directly owns 321,203 shares of the company’s stock, valued at $2,990,399.93. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 90,098 shares of company stock worth $843,933 and have sold 355,658 shares worth $6,955,732. 41.90% of the stock is owned by insiders.

WARNING: “Selecta Biosciences (SELB) Earns Daily Media Sentiment Score of 0.12” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/selecta-biosciences-selb-earns-daily-media-sentiment-score-of-0-12/1773067.html.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Insider Buying and Selling by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.